AA
GBT

AlphaCentric Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

AlphaCentric Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-225
Closed -$14K – 180
2020
Q2 		$14K Buy
+225
New +$15.4K 0.01% 129

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AlphaCentric Advisors's GBT Position: Q3 2020 in Review

AlphaCentric Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2020, closing a stake of 225 shares — an estimated $14K sold.

AlphaCentric Advisors first reported a position in GBT in Q2 2020 and held it in 1 quarter. The position peaked at $14K in Q2 2020. 229 funds tracked by Wall St. Rank hold GBT as of Q3 2020.

  • AlphaCentric Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • AlphaCentric Advisors sold 225 Global Blood Therapeutics, Inc. shares in Q3 2020, an estimated $14K.
  • AlphaCentric Advisors first reported a position in Global Blood Therapeutics, Inc. in Q2 2020 and held it in 1 quarter.
  • AlphaCentric Advisors's Global Blood Therapeutics, Inc. position peaked at $14K in Q2 2020.
  • 229 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2020.

Based on AlphaCentric Advisors's 13F filing for Q3 2020, filed 11 Mar 2022.